Celina M. D’Cruz

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.6kcitations114works7.42yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(28), Estrogen and related hormone effects(26), Advanced Breast Cancer Therapies(26), Renal cell carcinoma treatment(18), HER2/EGFR in Cancer Research(9)

Publications114 total

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
Annals of Oncology·2025Open Access
Abstract P2-03-19: Capivasertib-fulvestrant for patients w/ HR-pos/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial
Clinical Cancer Research·2025· 1 cited
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
ESMO Open·2024· 13 citedOpen Access
LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Annals of Oncology·2024· 8 citedOpen Access
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Oncology·2024· 32 cited
Abstract PS02-02: Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer
Cancer Research·2024· 2 cited
Abstract PS17-03: Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial
Cancer Research·2024· 3 cited
Abstract PO2-19-10: CAPItello-292 Phase 3: An open-label, randomized study of capivasertib, fulvestrant, and investigator’s choice of CDK4/6 inhibitor (palbociclib or ribociclib) in HR+/HER2– advanced breast cancer
Cancer Research·2024· 4 cited
183MO Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
ESMO Open·2024· 4 citedOpen Access
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
Journal of Clinical Oncology·2023· 4 cited
Data from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
Data from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
Supplementary Tables 1 through 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
Data from Tumors with AKT1<sup>E17K</sup> Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2023Open Access
Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Data from Tumors with AKT1<sup>E17K</sup> Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2023Open Access
Data from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
Supplementary Figure legends from Tumors with AKT1<sup>E17K</sup> Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2023Open Access
Supplementary methods from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Evan Barry(10), Michael Zinda(10), Melanie M. Frigault(9), Komal Jhaveri(9), Lewis A. Chodosh(8), Alwin G. Schuller(8), Ryan E. Henry(8), Garry Beran(8), Corinne Reimer(7), Sacha J. Howell(7), Meena Okera(7), Lyudmila Zhukova(7), Nicholas C. Turner(7), Brendon Ladd(6), Anne Marie Mazzola(6), Michael Grondine(6), Barry R. Davies(6), Stephen E. Fawell(6), Edwin Clark(6), Alexandra Borodovsky(6)